Valuation: CARsgen Therapeutics Holdings Limited

Market Cap 5.23B 6.17B 786M 701M 645M 586M 1.1B 74.86B 1.12B 7.72B 3.08B 39.21B 2.95B 2.89B 124B P/E 2026 *
-35.8x
P/E 2027 * -99.9x
Enterprise Value 4.28B 5.05B 644M 574M 529M 480M 899M 61.33B 918M 6.32B 2.52B 32.12B 2.42B 2.37B 102B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 6.59x
Free-Float
62.5%
Yield 2026 *
-
Yield 2027 * -
10-25 CARsgen Therapeutics Holdings Limited Presents Preliminary Positive Research Results Of Satri-Cel For Adjuvant Treatment For Locally Advanced Gastric Or Gastroesophageal Junction Cancer At ESMO Congress 2026 CI
10-12 CARsgen Doses First Patient in China Trial of T-Cell Therapy for Multiple Myeloma MT
10-12 Carsgen Therapeutics Holdings Limited Completes First Patient Dose of Ct0596 in China Phase I Registrational Trial CI
09-30 Carsgen Therapeutics Holdings Limited Announces Resignation of Huaqing Guo as Non-Executive Director and Member of the Audit Committee, Effective September 30, 2026 CI
09-28 CARsgen Therapeutics Doses First Patient in CT1190B Lymphoma Trial MT
09-28 Carsgen Therapeutics Holdings Limited Completes First Patient Dose of Ct1190b in China Phase I Registrational Trial CI
09-14 Tranche Update on CARsgen Therapeutics Holdings Limited's Equity Buyback Plan announced on October 21, 2025. CI
08-18 CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-13 Certain Ordinary Shares of CARsgen Therapeutics Holdings Limited are subject to a Lock-Up Agreement Ending on 14-AUG-2026. CI
08-07 CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy MT
08-04 CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3% MT
08-03 CARsgen Therapeutics Holdings Limited Announces CT0596 Receives IND Clearance from NMPA for Treatment of Relapsed/Refractory Multiple Myeloma CI
07-14 CARsgen Therapeutics Holdings Limited Research Results On Satri-Cel Accepted For Poster Presentation At ESMO Congress 2026 CI
1 day-2.67%
1 week-8.75%
Current month-13.10%
1 month-10.17%
3 months-16.92%
6 months-51.89%
Current year-26.26%
1 week 10.47
Extreme 10.47
11.55
1 month 10.47
Extreme 10.47
13
Current year 10.47
Extreme 10.47
28.6
1 year 10.47
Extreme 10.47
28.6
3 years 2.48
Extreme 2.48
28.6
5 years 2.48
Extreme 2.48
49.7
10 years 2.48
Extreme 2.48
57.25
Manager TitleAgeSince
Chief Operating Officer 49 2021-01-31
Chief Executive Officer 52 2021-01-31
Director of Finance/CFO 54 2021-02-28
Director TitleAgeSince
Chairman 52 2021-02-22
Director/Board Member 49 2018-09-12
Director/Board Member 40 2020-09-17
Date Insider Type Main position Quantity % Market Cap. Importance
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
Change 5-day change 1-year change 3-year change Capi.($)
-2.67%-8.75%-33.27%+9.50% 806M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.57%+2.82%+43.62%+147.88% 39.33B
Weighted average by Cap. -0.08%+3.11%+49.09%+160.57%

Financials

2026 *2027 *
Net sales 296M 349M 44.54M 39.72M 36.56M 33.2M 62.14M 4.24B 63.44M 437M 174M 2.22B 167M 164M 7.02B 659M 777M 99.08M 88.36M 81.34M 73.86M 138M 9.43B 141M 973M 388M 4.94B 372M 364M 15.62B
Net income -149M -176M -22.39M -19.97M -18.38M -16.69M -31.24M -2.13B -31.9M -220M -87.6M -1.12B -84.03M -82.24M -3.53B -55.4M -65.35M -8.33M -7.43M -6.84M -6.21M -11.62M -793M -11.87M -81.76M -32.59M -415M -31.26M -30.59M -1.31B
Net Debt -945M -1.11B -142M -127M -117M -106M -198M -13.53B -202M -1.39B -556M -7.08B -533M -522M -22.4B -889M -1.05B -134M -119M -110M -99.68M -187M -12.73B -190M -1.31B -523M -6.67B -502M -491M -21.08B
Projected Income Statement - Annual - CARsgen Therapeutics Holdings Limited
Logo CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
Employees
424
Date Price Change Volume
26-10-29 HK$10.95 -2.67% 1,352,000
26-10-28 HK$11.25 0.00% 861,343
26-10-27 HK$11.25 +0.72% 1,473,500
26-10-26 HK$11.17 -0.36% 765,500
26-10-23 HK$11.21 +3.60% 1,420,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - CARsgen Therapeutics Holdings Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
9.301CNY
Average target price
15.74CNY
Spread / Average Target
+69.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CARsgen Therapeutics Holdings Limited
  1. Stock Market
  2. Stocks
  3. 2171 Stock